Stock analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the stock.
Several other equities analysts have also recently issued reports on VNRX. D. Boral Capital reiterated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Wednesday, January 8th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.
Check Out Our Latest Report on VolitionRx
VolitionRx Stock Up 1.4 %
Insider Activity
In related news, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.
Hedge Funds Weigh In On VolitionRx
An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) by 15.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
- Five stocks we like better than VolitionRx
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a buyback in stocks? A comprehensive guide for investors
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.